CIRT

Low-dose methotrexate for the prevention of atherosclerotic events - The New England Journal of Medicine - 2018

Brief Summary:

In patients with established atherosclerotic heart disease (previous MI or multivessel coronary disease plus either type 2 diabetes or metabolic syndrome), low-dose methotrexate failed to reduce the primary endpoint of nonfatal MI, nonfatal stroke, hospitalization for unstable angina leading to revascularization, or cardiovascular death after 2.3 years.

Reference:
http://www.ncbi.nlm.nih.gov/pubmed/30415610